← IndicationsOpen filtered programs
Landscape
Ototoxicity
Ototoxicity has 11 tracked records across 3 named organizations, including 0 strong-evidence records and 7 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
11
Pipeline Records
strong evidence + caveats + candidates
0
Strong Evidence
11 checked records with caveats
7
Active Programs
currently active
0
Marketed / Approved
commercial or approved
3
Organizations
companies, sponsors, and institutions
Competitive Density
13/100
organization breadth + program volume
Pipeline Velocity
47/100
active and late-stage share
Evidence Coverage
0/100
share strong evidence
Completion Signal
9/100
late-stage, approved, or marketed
Attrition Rate
9/100
share discontinued
Concentration
82/100
top-organization share
Programs by Stage
Phase 11 · 9%
Phase 25 · 45%
Phase 31 · 9%
Expanded Access1 · 9%
Interventional/NA1 · 9%
Not applicable2 · 18%
Trial / Program Status
Active7 · 64%
Completed2 · 18%
Discontinued1 · 9%
Unknown1 · 9%
Modality Breakdown
Small Molecule8 · 73%
Drug Delivery2 · 18%
Genetic/Biomarker Study1 · 9%
Program Types
Therapeutic10 · 91%
Diagnostic1 · 9%
Top Organizations
Institution-led study9 · 82%
Investigator-led study1 · 9%
TRPHARM1 · 9%
Population Tags
cisplatin-ototoxicity10 · 91%
adult9 · 82%
otoprotection7 · 64%
cancer3 · 27%
head-and-neck-cancer2 · 18%
pediatric2 · 18%
amikacin1 · 9%
expanded-access1 · 9%
genetic1 · 9%
hepatoblastoma1 · 9%
Strong-Evidence Programs
0 recordsNo strong-evidence records yet for this indication.
Checked Records With Caveats
11 recordsOHSU/Oricula ORC-13661 amikacin otoprotection studyStatus caveat
Sponsor / Institution: Investigator-led study · Phase 2 · Active
Small MoleculePhase 2Active83% confidence
AP-HP OTOPLAT platinum ototoxicity pharmacogenetics studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Genetic/Biomarker StudyNot applicableCompleted88% confidence
Aspirin cisplatin-ototoxicity prevention studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Unknown
Small MoleculeNot applicableUnknown84% confidence
NIDCD atorvastatin cisplatin otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
Small MoleculePhase 2Active84% confidence
NKI SOUND transtympanic sodium thiosulfate cisplatin otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 3 · Active
Drug DeliveryPhase 3Active84% confidence
TRPHARM sodium thiosulfate compassionate use programStatus caveat
Company: TRPHARM · Expanded Access · Active
Small MoleculeExpanded AccessActive84% confidence
Siriraj N-acetylcysteine cisplatin otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
Small MoleculePhase 2Active82% confidence
University of Brasilia Ginkgo biloba cisplatin otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed82% confidence
City of Hope Pedmark adult testicular-cancer otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1 · Active
Small MoleculePhase 1Active82% confidence
Sunnybrook sodium thiosulfate plus mannitol cisplatin otoprotection studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Active
Small MoleculePhase 2Active82% confidence
Intratympanic sodium thiosulfate otoprotection pilot studyStatus caveat
Sponsor / Institution: Institution-led study · Interventional/NA · Discontinued
Drug DeliveryInterventional/NADiscontinued82% confidence